

Product Data Sheet

AX-024 hydrochloride

Cat. No.: HY-107390A CAS No.: 1704801-24-0 C₂₁H₂₃ClFNO₂ Molecular Formula:

Molecular Weight: 375.86

Target: TNF Receptor; Interleukin Related; IFNAR Pathway: Apoptosis; Immunology/Inflammation 4°C, sealed storage, away from moisture Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro DMSO: 33 mg/mL (87.80 mM; Need ultrasonic and warming)

H₂O: 16.67 mg/mL (44.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6606 mL	13.3028 mL	26.6057 mL
	5 mM	0.5321 mL	2.6606 mL	5.3211 mL
	10 mM	0.2661 mL	1.3303 mL	2.6606 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.65 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.65 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.65 mM); Clear solution

BIOLOGICAL ACTIVITY

Description AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-

triggered T cell activation with an IC $_{50}$ ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride $024\ hydrochloride\ has\ low-acute\ toxicity\ and\ high\ potency\ and\ selectivity,\ and\ strongly\ inhibit\ the\ production\ of\ IL-6,\ TNF-\alpha,$

IFN-γ, IL-10 and IL-17A.

IL-6 IL-10 IL-17A IC₅₀ & Target

In Vitro AX-024 hydrochloride is >10,000-fold more potent than the AX-000 hit in terms of inhibition of TCR-triggered T cell proliferation. The IC $_{50}$ of AX-024 hydrochloride in this assay is 1 nM, although it shows inhibitory effects at a concentration of 1 pM or less. AX-024 hydrochloride is also a much more potent inhibitor of cytokine release by human peripheral blood mononuclear cells stimulated with anti-CD3 than AX-000, strongly hindering interleukin-6 (IL-6), tumor necrosis factor- α (TNF α), interferon- γ (IFN- γ), IL-10, and IL-17A production at a concentration of 10 nM. In CD8⁺ T cells of OT1 TCR transgenic (OT1^{Tg}) mice bearing wild-type (WT) AX-024 hydrochloride strongly inhibits T cell proliferation at a concentration of 0.1 nM when OT1^{Tg} T cells are WT for the PRS mutation. Coimmunoprecipitation experiments in these cells show that Nck recruitment to the TCR is induced upon stimulation in the absence of drug but is inhibited in the presence of AX-024 hydrochloride in a dose-dependent manner at concentrations starting from 1 nM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The AX-024 hydrochloride-treated group presents less scales and reduces skin thickening compare to the vehicle group. AX-024 hydrochloride significantly reduces thickening of both skin layers, but more effectively of the dermis, which rather resembles that of mice treated with a control cream lacking imiquimod (IMQ). AX-024 hydrochloride significantly diminishes the number of airway inflammatory cells in both assays. Mice receiving AX-024 hydrochloride rapidly recovers from neurological impairment and weight loss, becoming symptom-free by day 30, unlike mice that receives the vehicle, in which ataxia and loss of the righting reflex persist^[1].

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

PROTOCOL

Cell Assay [1]

Spleen B cells from C57BL/6 mice are labeled with Cell Trace Violet and incubated for 72 hours with either anti-IgM (10 mg/mL) or anti-CD40 (5 mg/mL), supplemented with IL-4 (5 ng/mL) or LPS (2.5 mg/mL) in the presence of different concentrations of AX-024 hydrochloride. Proliferation is calculated according to the total number of cell divisions^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal
Administration [1]

Eight-week-old CD-1 mice are injected intraperitoneally with different amounts of the AX-024 hydrochloride dissolved in 0.5 mL of saline. All animals are observed clinically for the appearance of macroscopically visible adverse reactions twice daily over 14 days, as well as immediately after AX-024 hydrochloride administration. A necropsy is carried out on each animal on day 14, and the abdominal, thoracic, and cranial cavities are examined in situ, together with their associated organs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

· Life Sci. 2020 May 1;248:117456.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Borroto A, et al. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases. Sci Transl Med. 2016 Dec 21;8(370):370ra184.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com